Articles tagged with Glioblastomas
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have discovered potential regulatory networks in glioblastoma using microRNAs and transcription factors. The study identified 54 feed-forward loops with functions important to carcinogenesis and unique functions specific to each FFL.
A Phase I clinical trial found that the experimental vaccine ICT-107 targets six antigens found on glioblastoma cells and three on cancer stem cells, improving immune responses and progression-free survival rates in patients. The study also showed that targeting these antigens may be a viable strategy for treating glioblastoma.
A new glioblastoma vaccine has demonstrated safety and effectiveness in a Phase 2 clinical trial, extending median survival to 11 months for patients with recurrent brain cancer. The vaccine was found to induce an immune response against tumor-specific targets, suggesting potential for improved treatment outcomes.
Survival rates for wealthier patients with glioblastoma have improved since 2000, while those in poorer areas and older than 70 have remained stagnant. The addition of temozolomide to post-operative radiation therapy has been shown to improve overall survival in younger patients.
The RTOG 0525 Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma found no significant improvement in overall patient survival or disease progression for patients who received dose-intensive temozolomide plus radiotherapy. However, the trial demonst...
Researchers at IDIBELL found that Nutlin-3a stimulates the p53 pathway, inducing apoptosis and cellular senescence in brain cancer cells. This study suggests MDM2 antagonists may be new therapeutic options for glioblastoma treatment.
A team of University of Cincinnati researchers is sequencing individual glioblastoma genomes and tracking abnormalities in the bloodstream to establish personalized biomarkers. The study aims to guide treatment efforts and identify new therapeutic targets for this aggressive brain tumor.
A personalized dendritic cell vaccine has been shown to increase median survival time in patients with glioblastoma, a deadly form of brain cancer. The vaccine was found to be effective in patients with the mesenchymal subtype of glioblastoma, which accounts for about one-third of all cases.
Glioblastoma cells can transform into blood vessel cells when oxygen is scarce, making treatment efforts less effective. This transformation allows the tumor cells to continue receiving nutrients and oxygen, leading to a resurgence of cancer growth.
A recent study published in the New England Journal of Medicine found that losing the NFKBIA gene promotes glioblastoma multiforme growth and reduces survival. Restoring this gene may improve survival for certain patients with glioblastoma, as it inhibits tumor cell growth and increases sensitivity to chemotherapy.
Researchers at Stanford Medicine have discovered a gene deletion in up to one-fourth of glioblastoma cases, a type of brain cancer with poor survival prospects. The deletion contributes to tumor growth, resistance to therapy, and worsens patient outcomes.
Phase III trial data suggests Tumor Treating Fields (TTF) therapy increases median survival time and improves quality of life scores compared to standard chemotherapy. Younger patients and those with better functional status show an impressive survival advantage.
A new vaccine has been shown to extend survival for patients with glioblastoma, the most deadly form of brain cancer, by eliminating aggressive cancer cells carrying the EGFRvIII marker. The study found that adding the vaccine to standard therapy improved median survival time from 15 months to 26 months.
A team of researchers has discovered genetic changes in glioblastoma, a common type of primary brain cancer, that contribute to its aggressiveness. The study found that tumors with rearrangements in receptor genes are more common than previously thought, suggesting new targets for therapies.
A novel combination therapy of temozolomide and a Notch inhibitor has been shown to be highly effective in reducing tumor growth and recurrence in glioblastoma multiforme. This approach aims to target cancer stem cells, which are resistant to traditional therapies.
Researchers have identified a new cellular communication mechanism in glioblastoma cells, which could be targeted to slow tumor growth. If blocked, this pathway may significantly reduce GBM malignancy.
Researchers at Wake Forest University Baptist Medical Center have identified a way to target and destroy Glioblastoma multiforme (GBM) cells without harming healthy cells. The breakthrough allows for new possibilities in cancer research, potentially leading to less toxic and invasive treatments.
The study enrolled 237 patients with recurrent GBM and found that NovoTTF was as effective as the best available chemotherapies without the toxicity. Patients treated with NovoTTF lived longer and experienced fewer infections compared to chemotherapy.
A new drug, PD-0332991, has been found to effectively block the growth of glioblastoma cells in laboratory tests and animal studies. The agent targets specific molecules that drive cell division in cancer cells, offering a potential new treatment option for this deadly form of brain cancer.
Researchers at Stanford University School of Medicine found that blocking blood vessel formation prevents brain tumor recurrence in mice. Disrupting the SDF-1/CXCR4 interaction prevented tumor regrowth by abrogating functional tumor vasculature.
Researchers at Stanford University School of Medicine have found that disrupting the SDF-1/CXCR4 interaction can prevent the recruitment of vasculogenic cells to the tumor site, blocking postirradiation development of functional tumor vasculature and tumor regrowth. This approach may be applicable to treating glioblastoma multiforme.
The Cancer Genome Atlas reveals four molecular subtypes of glioblastoma multiforme (GBM), the most common form of malignant brain cancer in adults. Researchers found that response to chemotherapy and radiation differed by subtype, with some subtypes experiencing a 50% slower disease progression.
Researchers at UNC Lineberger Comprehensive Cancer Center identified four distinct molecular subtypes of GBM, each associated with a specific disease process. The study provides a solid framework for investigation of future targeted therapies that may improve the prognosis of this devastating cancer.
Researchers from M.D. Anderson Cancer Center discovered that cancer stem cells inhibit T cell response and evade immune attack on glioblastoma multiforme. Differentiation of these cells into other neural types can restore the immune response, offering new hope for treatment.
Researchers have identified two genes, C/EPB and Stat3, which are responsible for the most aggressive forms of human brain cancer. These genes work together to transform normal brain cells into highly aggressive cells, making them a major target for new treatments.
Researchers at the University of Central Florida have found a protein, TRPC6, that could hold the key to treating GBM, a type of malignant brain tumor. Knocking down this protein's expression can stop tumor growth and spread.
Researchers at University Hospitals Case Medical Center report promising results from a study treating glioblastoma multiforme with Gamma Knife radiosurgery, increasing patient survival rates by almost four months compared to traditional radiotherapy alone.
A Phase II study shows Avastin significantly increases response rates, progression-free survival times and survival rates in patients with recurrent glioblastoma. The treatment was found to be effective both alone and in combination with chemotherapy, improving patient outcomes and quality of life.
Researchers funded by NIH have found a key factor in the spread of aggressive brain cancer glioblastoma multiforme (GBM). A small designer protein can block the activity of a protein fragment that stimulates GBM cell migration, suggesting a potential new therapy target.
Researchers found that STAT3 inhibits the growth and self-renewal of glioblastoma stem cells, suggesting a promising target for cancer therapy. The study demonstrates the potential of STAT3 inhibitors to stop tumor formation and offers a new approach to treating this devastating brain cancer.
Glioblastoma, the deadliest form of brain cancer, has shown promise in treating with an engineered antibody that shuts down tumor growth. Researchers at Lombardi Comprehensive Cancer Center successfully tested the antibody in human cells and animal studies.
A network of 31 mutated genes has been identified as the driving force behind glioblastoma growth. Annexin A7, a vital guard gene, is lost in most cases, allowing tumors to flourish. The discovery offers new therapeutic targets and potentially extends patient survival.
Recent JAMA studies on brain cancer and altered genes have made significant progress in understanding the root causes of this deadly disease. Researchers identified seven genes linked to survival among glioblastoma multiforme patients, paving the way for potential new therapies.
Researchers at UNC School of Medicine have identified a compound that could treat secondary glioblastoma multiforme (GBM), a type of brain tumor. By replenishing α-ketoglutarate, they reversed the effects of IDH1 gene mutation, which contributes to tumor growth.
Researchers at Duke University have identified a receptor on human glioblastoma cells that may be an appropriate target for therapies. Activation of the neurokinin 1 receptor leads to increased cell growth, but blocking this activity can reduce cell death and potentially stall cancer growth.
Researchers at UT Southwestern Medical Center have identified a new biological indicator, RIP1, that may help identify the most aggressive forms of adult brain cancer. High levels of RIP1 are commonly found in glioblastoma tumors and are associated with poor prognosis and resistance to chemotherapy.
The study found that treatment with cediranib reduced edema and improved survival in mice with glioblastoma tumors. Mice receiving the drug lived significantly longer than controls, despite continued tumor growth.
The EORTC-NCIC trial found that adding chemotherapy to radiotherapy significantly increases survival in glioblastoma patients, with improved outcomes seen across all clinical prognostic subgroups. The study suggests testing tumour MGMT gene methylation status to identify patients most likely to benefit from this treatment.
Researchers at Bonn University discovered a critical improvement in treating glioblastoma, the most aggressive and common brain tumor. The combination of two drugs increased average survival time to 23 months, with some patients surviving over four years. Further investigations are needed to optimize this therapy.
Scientists have identified two gene mutations, IDH1 and IDH2, linked to nearly three-quarters of gliomas, a type of brain cancer. These mutations are associated with longer survival rates in patients with certain types of gliomas. Further research may lead to more precise diagnoses and treatments.
Scientists at Duke University Medical Center and Johns Hopkins University have identified two genes with potential as therapeutic targets for malignant glioma, a deadly class of brain tumors. IDH1 mutations were found in over 70% of astrocytomas and olidgodendrogliomas, associated with longer survival times.
A study found that elderly patients with glioblastoma are less likely to undergo surgery, radiation, or chemotherapy due to concerns about toxic side effects. The median survival for these patients was only four months.
Researchers have identified a mechanism for an effective immune response to brain tumors by combining immunotherapy and strategies to kill tumor cells. The study suggests that this combination may provide effective treatment for glioblastoma multiforme, the most aggressive form of brain cancer.
The Novo-TTF device was shown to enhance the efficacy of standard chemotherapy in treating newly-diagnosed glioblastoma multiforme patients. Combination therapy with the device prolonged time to disease progression by nearly 31 months and increased survival by more than 25 months compared to historical results.
A family history of brain tumors is linked to a higher risk of developing the same type of tumor. Researchers found that people with immediate relatives who suffered from glioblastomas or astrocytomas were nearly four and twice as likely to contract the same kind of brain cancer, respectively.
The Cancer Genome Atlas reports findings on the MGMT gene, which makes brain cancer cells more responsive to treatment but also leads to mutations in other genes essential for DNA repair. These mutations contribute to cancer recurrence and resistance to treatment.
The Cancer Genome Atlas identifies new genetic mutations, including NF1, ERBB2, and PIK3R1, and core pathways disrupted in glioblastoma. The study provides an unprecedented overview of the genomic landscape of this deadly cancer.
A large-scale study has identified a range of genetic mutations and signaling pathways disrupted in glioblastoma, the most common adult brain cancer. The findings validate the potential of unbiased genome analysis to lead to paradigm-shifting discoveries and identify new targets for treatment.
A team of researchers has conducted a comprehensive analysis of genomic variation in glioblastoma, the most common and aggressive primary brain tumor. The study's findings highlight the importance of integrating genomic and epigenomic measurements to better understand cancer genetics.
Researchers have discovered a mechanism to overcome the resistance of human glioblastoma multiforme cells to growth factor inhibitors by blocking inhibitor of apoptosis proteins. Combining drugs targeting IAPs with RTK inhibitors showed enhanced efficacy in inhibiting tumor growth. Additionally, targeting liver CB1 receptors may provid...
Researchers found that RTK inhibitors can be less effective in treating glioblastoma multiforme (GBM) due to cell death inhibition. Combining RTK and IAP inhibitors showed promise in inducing apoptosis in GBM cells, with enhanced efficacy in orthotopic mouse models.
A new vaccine targets glioblastoma multiforme, doubling survival time and more than quadrupling progression-free survival. The vaccine has caused virtually no side effects, making it a promising therapy for this deadly brain tumor.
A new vaccine targeting human cytomegalovirus (CMV) shows promise in delaying the recurrence of deadly brain tumors, glioblastoma multiforme (GBM). The study found that patients receiving the vaccine experienced a significant delay in tumor regrowth, with overall survival extended to over 20 months.
The Novo-TTF device demonstrated significant efficacy in reducing tumor volume and improving outcomes for patients with locally advanced breast cancer. The device's non-invasive technology disrupts cancer cell proliferation, offering a potential alternative to traditional chemotherapy.
Researchers have validated genetic aberrations and identified new targets for GBM treatment. A novel regulatory circuit involving INK4 family genes, p18INK4C and p16INK4A, constrains inappropriate glial cell proliferation and enhances tumorigenicity.
Researchers found that CD95 on glioblastoma cells is activated by CD95L, leading to the production of MMP9, which cuts through tissue layers and allows cancer cells to invade healthy tissue. Blocking this activation may be a new approach to stopping glioblastoma's spread.
Researchers developed gene therapy approach that attracts and 'trains' immune system cells to destroy deadly brain cancer cells, promoting long-term immunity and restoring normal brain function. The therapy shows promise as a potential treatment for glioblastoma multiforme, the most common and deadly type of brain cancer.
Researchers found that STAT3 has tumor-promoting and tumor-suppressing effects depending on the genetic profile of glioblastoma tumors. This discovery highlights the need for effective therapies tailored to individual glioblastoma tumors.
A study published in the Journal of Neurosurgery found that simultaneous implantation of radioactive seeds and chemotherapy wafers following surgery improved patient survival rates for recurrent glioblastoma multiforme (GBM) patients. The median survival was 69 weeks, with nearly a quarter of patients surviving two years.
Researchers developed a three-drug cocktail targeting glioblastoma multiforme tumors, which showed significant benefits in killing cancer cells and sparing healthy brain tissue. The treatment is based on the first-ever documented molecular signature of GBM tumors and may be tested in patients within five years.